Core Viewpoint - The announcement details the results of the stock option and restricted stock incentive plan for the second quarter of 2025, indicating no shares were exercised during this period. Summary by Sections Stock Option Exercise Results - The total number of stock options available for exercise in the third exercise period of the 2021 stock option and restricted stock incentive plan is 1,976,997 shares, with the exercise start date on January 17, 2025. As of June 30, 2025, no shares have been exercised, representing 0% of the total available for this period [1][12]. - For the reserved stock options in the second exercise period, the total available is 738,491 shares, with the exercise start date on December 25, 2024. Similarly, no shares have been exercised as of June 30, 2025, also representing 0% of the total available [1][12]. Decision-Making Process and Disclosure - The decision-making process for the stock option exercise involved independent directors providing consent and avoiding conflicts of interest during the voting on related proposals [2][3]. Stock Option and Restricted Stock Plan Adjustments - The number of incentive participants was adjusted from 327 to 302 due to 25 participants voluntarily giving up their participation. The total number of stock options remains at 3,865,060, with a grant price of 32.26 CNY per option and restricted stock at 16.13 CNY per share [6][7]. Stock Listing and Trading Arrangements - The stock options from the third exercise period and the reserved options from the second exercise period will be exercised through a self-exercise method, with shares listed for trading on the second trading day after the exercise date [11][12]. Impact on Financial Reports - The exercise of stock options is not expected to have a significant impact on the company's financial condition or operating results [14].
美诺华: 宁波美诺华药业股份有限公司关于2021年股票期权与限制性股票激励计划2025年第二季度自主行权结果暨股份变动公告